Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oryzon GenomicsORYZF +1.45%33 Current Ratio is 1.60 as of Jun. 2026, which is 49% below its 10-year median of 3.12. GuruFocus rates ORYZF with a GF Score™ of 33/100. Among 1,407 Biotechnology companies, Oryzon Genomics ranks worse than 73.77% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Oryzon Genomics's current ratio for the quarter that ended in Jun. 2026 was 1.60.
Oryzon Genomics has a current ratio of 1.60. It generally indicates good short-term financial strength.
The historical rank and industry rank for Oryzon Genomics's Current Ratio or its related term are showing as below:
ORYZF'
s Current Ratio Range Over the Past 10 Years
Min: 0.75 Med: 3.12 Max: 6.39
Current: 1.6
During the past 12 years, Oryzon Genomics's highest Current Ratio was 6.39. The lowest was 0.75. And the median was 3.12.
ORYZF's Current Ratio is ranked worse than 73.77% of 1407
companies
in the Biotechnology industry
Industry Median: 3.83
vs ORYZF: 1.60
Oryzon Genomics (OTCPK:ORYZF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Oryzon Genomics Current Ratio Related Terms
Oryzon Genomics Current Ratio Historical Data
* Premium members only.
The historical data trend for Oryzon Genomics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORYZF vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Oryzon Genomics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oryzon Genomics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oryzon Genomics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Oryzon Genomics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oryzon Genomics (ORYZF) has a Current Ratio of 1.60 as of Jun. 2026. This is 49% below median its historical median of 3.12. Over the past decade, Oryzon Genomics' Current Ratio has ranged from 0.75 to 6.39. According to the industry distribution chart, Oryzon Genomics ranks #1038 out of 1407 companies in the Biotechnology industry, placing it in the top 73.8%.
Is Oryzon Genomics' Current Ratio too high?
Oryzon Genomics' current Current Ratio of 1.60 is 49% below median its 10-year median of 3.12. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 6.39. The Biotechnology industry median Current Ratio is 3.83. Oryzon Genomics' value of 1.60 is 58.2% below this industry median. Based on the distribution chart, Oryzon Genomics ranks #1038 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oryzon Genomics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oryzon Genomics ranks #1038 out of 1407 companies for Current Ratio. This places Oryzon Genomics in the lower half of its industry. The industry median Current Ratio is 3.83. Oryzon Genomics' value of 1.60 is 58.2% below this benchmark. Historically, Oryzon Genomics' own Current Ratio has ranged from 0.75 to 6.39 over the past decade. While the company's 10-year median is 3.12 vs. the industry median of 3.83, Oryzon Genomics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.83, based on 1,407 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oryzon Genomics's current Current Ratio of 1.60 is 58.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oryzon Genomics's current Current Ratio is 1.60, which is 49% below median its own 10-year median of 3.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current Current Ratio of 1.60. The current Current Ratio is 1.60, which is 49% below median its 10-year median of 3.12 and 58.2% below the Biotechnology industry median of 3.83. Oryzon Genomics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current Current Ratio is 1.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
33GF Score
Get the complete analysis for ORYZF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORYZF has been successfully added to your 
